Covid-19 roundup: In fifth open letter, Daniel O’Day touts inhalant remdesivir, promises 2M doses by year's end; Merck’s antiviral moves into PhII

John Carroll

Editor & Founder

Jason Mast

Editor

Since remdesivir began capturing treatment hopes early in the outbreak, one clear factor has limited its potential: Antivirals are known to work best in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: In fifth open letter, Daniel O’Day touts inhalant remdesivir, promises 2M doses by year's end; Merck’s antiviral moves into PhII

John Carroll

Editor & Founder

Jason Mast

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Compounded weight loss drugs have resulted in misdosing, hospitalizations, FDA warns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Covid-19 roundup: In fifth open let­ter, Daniel O’Day touts in­halant remde­sivir, promis­es 2M dos­es by year's end; Mer­ck’s an­tivi­ral moves in­to PhII

Editor & Founder

Editor

Sign up to read this article for free.

Covid-19 roundup: In fifth open letter, Daniel O’Day touts inhalant remdesivir, promises 2M doses by year's end; Merck’s antiviral moves into PhII